- Home
- IDR vs VTYX Comparison
IDR vs VTYX Comparison
Compare IDR & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- VTYX
- Stock Information
- Founded
- IDR 1996
- VTYX 2018
- Country
- IDR United States
- VTYX United States
- Employees
- IDR N/A
- VTYX N/A
- Industry
- IDR Precious Metals
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- IDR Basic Materials
- VTYX Health Care
- Exchange
- IDR Nasdaq
- VTYX Nasdaq
- Market Cap
- IDR 142.7M
- VTYX 154.9M
- IPO Year
- IDR N/A
- VTYX 2021
- Fundamental
- Price
- IDR $11.92
- VTYX $2.08
- Analyst Decision
- IDR Strong Buy
- VTYX Buy
- Analyst Count
- IDR 1
- VTYX 4
- Target Price
- IDR $14.00
- VTYX $11.33
- AVG Volume (30 Days)
- IDR 128.7K
- VTYX 1.9M
- Earning Date
- IDR 11-04-2024
- VTYX 02-25-2025
- Dividend Yield
- IDR N/A
- VTYX N/A
- EPS Growth
- IDR 344.27
- VTYX N/A
- EPS
- IDR 0.52
- VTYX N/A
- Revenue
- IDR $21,955,008.00
- VTYX N/A
- Revenue This Year
- IDR $86.37
- VTYX N/A
- Revenue Next Year
- IDR $11.11
- VTYX N/A
- P/E Ratio
- IDR $23.18
- VTYX N/A
- Revenue Growth
- IDR 64.93
- VTYX N/A
- 52 Week Low
- IDR $5.75
- VTYX $1.67
- 52 Week High
- IDR $18.35
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- IDR 60.99
- VTYX 45.64
- Support Level
- IDR $10.55
- VTYX $1.83
- Resistance Level
- IDR $10.81
- VTYX $2.61
- Average True Range (ATR)
- IDR 0.51
- VTYX 0.18
- MACD
- IDR 0.24
- VTYX -0.03
- Stochastic Oscillator
- IDR 75.77
- VTYX 32.26
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.